; and (2) by adding at the end, the following new subclause: (IV) For each of 2020 through 2024, the productivity adjustment described in subclause (II) shall be zero for a payment system in any year in which the Medicare Payment Advisory Commission estimates that payments under this title pursuant to such payment system, on an aggregate national basis, exceed costs, on an aggregate national basis, by 3.0 percent or less. . (d) Payment for new and innovative drugs and biologicals that are renal dialysis services Section 1881(b)(14) of the Social Security Act ( 42 U.S.C. 1395ww(b)(14) ), as amended by subsections (a) and (b), is amended by adding the following new subparagraph— (L) Payment for new and innovative drugs, biologicals, and devices that are renal dialysis services (i) In general For drugs or biologicals determined to be within a functional category, the Secretary, in consultation with stakeholders, shall ensure that the single payment amount is adequate to cover the cost of new innovative drugs or biologicals and increase the single payment amount if the Secretary determines such payment amount is not adequate to cover such cost. In carrying out the preceding sentence, the Secretary shall use the cost and utilization data collected during the two-year transitional payment period, as described in the final regulation published on November 14, 2018 (83 Fed. Reg. 56922 et seq.). (ii) Money to follow the patient The Secretary, through notice and comment rulemaking, shall implement a policy for any drug or biological that is not provided to the average patient that results in the amount by which the single payment amount is increased pursuant to this subparagraph shall be paid only when a provider or renal dialysis facility has demonstrated that it has administered the drug or biological to a patient. . (e) New devices and other technologies As part of the promulgation of the annual rule for the Medicare end stage renal disease prospective payment system under section 1881(b)(14) of the Social Security Act